natgillin/translations-raw huggingface dataset:
Each metered dose of 1 gram of gel contains 90.7 mg of oxybutynin resulting in a nominal delivery of approximately 4 mg/day. 
En odmerjen odmerek z 1 gramom gela vsebuje 90,7 mg oksibutinina, kar predstavlja nominalno dovajanje približno 4 mg/dan.
Dry mouth, constipation, diarrhoea, nausea, abdominal pain 
Bolezni prebavil pogosti suha usta, obstipacija, diareja, navzea, bolečine v trebuhu občasni nelagoden občutek v trebuhu, dispepsija
Dizziness 
Čustva
Kentera 90.7 mg/g gel in sachet 
Kentera 90,7 mg/g gel v vrečici
Change from baseline P-value vs. placebo 
Vrednost P v primerjavi s placebom
- Overactive thyroid gland which can cause increased appetite, weight loss, or sweating - Narrowing of the blood vessels that supply blood and oxygen to the heart - Heart problems which can cause shortness of breath or ankle swelling - Irregular heart beat - Faster heart beat - High blood pressure - Enlarged prostate 
- napredujočo nevrološko bolezen, za katero so značilni tresenje počivajočih mišic, togost, počasnost gibov, okvare ravnotežja in podrsavajoč korak, - preveč aktivno ščitnico, ki lahko povzroči povečanje apetita, izgubo telesne mase ali potenje,
Application site erythema, application site reaction, application site rash 
bolečina na mestu aplikacije, pustule na mestu aplikacije
If you have any of the following: - Liver problems - Kidney problems - Difficulty urinating - Intestinal blockage - Bloody stools - Generalised muscle weakness - Painful swallowing - Unable to empty bladder during urination - Retained food in stomach after meals 
- nezmožnost popolnega praznjenja mehurja med uriniranjem, - zastajanje hrane v trebuhu po obroku,
Each metered dose of 1 gram of gel contains 90.7 mg of oxybutynin (as 100 mg oxybutynin hydrochloride) resulting in a nominal delivery of approximately 4 mg/day. 
En odmerjen odmerek z 1 gramom gela vsebuje 90,7 mg oksibutinina (v obliki 100 mg oksibutininijevega klorida), kar predstavlja nominalno dovajanje približno 4 mg/dan.
Metabolism and nutrition disorders 
Presnovne in prehranske motnje občasni hipokaliemija
Each sachet of 1 gram of gel contains 90.7 mg of oxybutynin (as 100 mg oxybutynin hydrochloride) resulting in a nominal delivery of approximately 4 mg/day. 
Ena vrečica z 1 gramom gela vsebuje 90,7 mg oksibutinina (v obliki 100 mg oksibutininijevega klorida), kar predstavlja nominalno dovajanje približno 4 mg/dan.
Kentera 90.7 mg/g gel in sachet oxybutynin 
Kentera 90,7 mg/g gel v vrečici oksibutinin
If you have any of the following: - Liver problems; - Kidney problems; - Difficulty urinating; - Intestinal blockage; - Bloody stools; - Generalised muscle weakness; - Painful swallowing; - Unable to empty bladder during urination; - Retained food in stomach after meals; 
- povejte zdravniku, če imate glavkom ali je kdo v družini imel glavkom; - če imate težave pri praznjenju mehurja; - če ne morete popolnoma izprazniti črevesa.
Upper respiratory tract infection, fungal infection 
Infekcijske in parazitske bolezni pogosti okužbe sečil občasni okužbe zgornjih dihal, glivične okužbe
The difference in AUC and Cmax of oxybutynin and the active metabolite N-desethyloxybutynin following transdermal administration of Kentera on either the abdomen, buttocks or hip is not clinically relevant. 
dezetiloksibutinina po nanosu transdermalnega obliža Kentera na trebuh, zadnjico ali boke ni klinično relevantna.
Talk to your doctor or pharmacist if you have any questions on the use of this medical product. 
Če imate kakršnakoli vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali farmacevtom.
If you have any of the following: - Liver problems - Kidney problems - Difficulty urinating - Intestinal blockage - Bloody stools - Generalized muscle weakness - Painful swallowing 
Bodite posebno pozorni pri uporabi zdravila Kentera če imate karkoli od navedenega: - težave z jetri, - težave z ledvicami, - težave pri uriniranju,
Read all of this leaflet carefully before you start using Kentera. 
Pred uporabo obliža Kentera natančno preberite priloženo navodilo!
How to use the multidose container with metering pump: 
VEČODMERNI VSEBNIK Z ODMERNO ČRPALKO
Urinary tract infection 
- zastajanje urina - težave pri uriniranju
Use with sunscreen 
Kako uporabljati obliž
Daily urinary frequency Baseline 
Vrednost P v primerjavi s placebom Dnevna pogostnost uriniranja
Total score 
Skupno število točk
Each metered dose of 1 gram of gel contains 90.7 mg oxybutynin (as hydrochloride) resulting in a nominal delivery of approximately 4 mg/day. 
En odmerjen odmerek z 1 gramom gela vsebuje 90,7 mg oksibutinina (v obliki klorida), kar predstavlja nominalno dovajanje približno 4 mg/dan.
Memory impairment#, amnesia#, lethargy#, disturbance in attention# 
Bolezni živčevja pogosti glavobol, zaspanost redki motnje spomina#, amnezija#, letargija#, motnje pozornosti#
Each sachet of 1 gram of gel contains 90.7 mg of oxybutynin (as hydrochloride) resulting in a nominal delivery of approximately 4 mg/day. 
Ena vrečica z 1 gramom gela vsebuje 90,7 mg oksibutinina (v obliki klorida), kar predstavlja nominalno dovajanje približno 4 mg/dan.
Avoid bathing, 
- zaprtje črevesa,
uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000). 
- redki (pojavijo se pri 1 do 10 bolnikov od 10.000 bolnikov); - zelo redki (pojavijo se pri manj kot 1 od 10.000 bolnikov);
Rhinitis 
Presnova
Where to apply 
Kje uporabljati obliž
- Quinidine (used to treat abnormal heart rhythms). 
- triciklični antidepresivi (uporabljajo se za zdravljenje depresije); - kinidin (uporablja se za zdravljenje nenormalnega srčnega ritma);
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or medicinal products with anticholinergic activity, such as amantadine and other anticholinergic antiparkinsonian medicinal products (e.g. biperiden, levodopa), antihistamines, antipsychotics (e.g. phenothiazines, butyrophenones, clozapine), quinidine, tricyclic antidepressants, atropine and related compounds like atropinic antispasmodics, and dipyridamole. 
- makrolidni antibiotik eritromicin (uporablja se za zdravljenje bakterijskih okužb); - biperiden, levodopa ali amantadin (uporabljajo se za zdravljenje Parkinsonove bolezni); - antihistaminiki (uporabljajo se za zdravljenje alergij, kot je alergija na pelodni prah); - fenotiazini, butirofenon ali klozapin (uporabljajo se za zdravljenje duševnih bolezni);
Panic reaction#, delirium#, hallucinations#, disorientation# 
Psihiatrične motnje občasni tesnoba, zmedenost, živčnost, vznemirjenost, nespečnost redki panična reakcija#, delirij#, halucinacije#, dezorientiranost#
Anxiety, confusion, nervousness, agitation, insomnia 
Psihiatrične motnje občasni tesnoba, zmedenost, živčnost, vznemirjenost, nespečnost redki panična reakcija#, delirij#, halucinacije#,
The frequency of possible side effects listed below is defined using the following convention: - Very common (affects more than 1 user in 10) - Common (affects 1 to 10 users in 100) - Uncommon (affects 1 to 10 users in 1,000) - Rare (affects 1 to 10 users in 10,000) - Very rare (affects less than 1 user in 10,000) - Not known (frequency cannot be estimated from the available data) 
Pogostnost spodaj navedenih možnih neželenih učinkov je razvrščena na naslednji način: - zelo pogosti (pojavijo se pri več kot 1 od 10 bolnikov),
Hydroxypropylcellulose Sodium hydroxide (for pH-adjustment) Purified water 
6 FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi etanol (96-odstoten) glicerol hidroksipropilceluloza natrijev hidroksid (za uravnavanje pH)
Impaired metabolism 
- splošno šibkost mišic,
Ear and labyrinth disorders 
(EPDM) in polipropilenske zaporke.
The frequency of possible side effects listed below is defined using the following convention: - Very common (affects more than 1 user in 10) - Common (affects 1 to 10 users in 100) - Uncommon (affects 1 to 10 users in 1,000) - Rare (affects 1 to 10 users in 10,000) - Very rare (affects less than 1 user in 10,000) - Not known (frequency cannot be estimated from the available data). 
- redki (pojavijo se pri 1 do 10 bolnikih od 10.000 bolnikov), - zelo redki (pojavijo se pri manj kot 1 bolniku od 10.000 bolnikov),
Middle layer 
Ned/Sre
Uncommon side effects - bladder infection - anxiety - confusion - nervousness - agitation - difficulty in sleeping - low blood levels of potassium which can cause muscle weakness, twitching or abnormal heart rhythm 
Bolezni živčevja pogosti glavobol, omotica občasni somnolenca, disgevzija, slaba kakovost spanja, tremor redki motnje spomina#, amnezija#, letargija#, motnje pozornosti#
Dry eye 
- suha koža,
Cardiac disorders 
Srčne bolezni občasni palpitacije
The European Commission granted a marketing authorisation valid throughout the European Union for Rebetol on 7 May 1999. 
Evropska komisija je dovoljenje za promet z zdravilom Rebetol, veljavno po vsej Evropski uniji, izdala 7. maja 1999.
What measures are being taken to ensure the safe and effective use of Rebetol? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rebetol?
Rebetol is taken with food each day in two divided doses (morning and evening). 
Zdravilo Rebetol se jemlje s hrano vsak dan v dveh deljenih odmerkih (zjutraj in zvečer).
The full EPAR for Rebetol can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Rebetol je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
It is available as capsules (200 mg) and as an oral solution (40 mg/ml). 
Na voljo je v obliki kapsul (200 mg) in peroralne raztopine (40 mg/ml).
A risk management plan has been developed to ensure that Rebetol is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Rebetol je bil pripravljen načrt obvladovanja tveganj.
Other information about Rebetol 
Druge informacije o zdravilu Rebetol
This is a summary of the European public assessment report (EPAR) for Rebetol. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Rebetol.
There are several other side effects of Rebetol, some of which are very common (occurring in more than 1 in 10 patients). 
Obstajajo tudi številni drugi neželeni učinki zdravila Rebetol, od katerih so nekateri zelo pogosti (pojavijo se pri več kot 1 bolniku od 10).
Children above 3 years of age and adolescents who weigh less than 47 kg or who cannot swallow capsules should take the oral solution at a dose of 15 mg per kilogram body weight a day. 
Otroci, starejši od treh let, in mladostniki, ki tehtajo manj kot 47 kg ali ki ne morejo pogoltniti kapsul, morajo jemati peroralno raztopino v odmerku 15 mg na kilogram telesne mase na dan.
The CHMP decided that Rebetol's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Rebetol večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
It can also be used in previously untreated patients aged three years and over whose livers are working properly. 
Prav tako se lahko uporablja pri predhodno nezdravljenih bolnikih, starejših od treh let, katerih jetra delujejo pravilno.
What benefit has Rebetol shown during the studies? 
Kakšne koristi je zdravilo Rebetol izkazalo med študijami?
For more information about treatment with Rebetol, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Rebetol preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is the risk associated with Rebetol? 
Kakšna tveganja so povezana z zdravilom Rebetol?
It has also been studied in 1,699 adults whose disease had come back after previous treatment or whose previous treatment had failed. 
Proučevali so ga tudi pri 1 699 odraslih, pri katerih se je bolezen ponovila po predhodnem zdravljenju ali pri katerih je bilo predhodno zdravljenje neuspešno.
Rebetol has been studied in a total of over 6,000 adults who had not been treated before, including 328 patients with cirrhosis and 507 patients also infected with HIV. 
Zdravilo Rebetol so proučili pri skupno več kot 6 000 odraslih, ki predhodno še niso bili zdravljeni, vključno s 328 bolniki s cirozo in 507 bolniki, ki so bili okuženi tudi z virusom HIV.
Rebetol has also been studied in 177 children and adolescents aged between three and 17 years who had not been treated before. 
Prav tako so ga proučili pri 177 otrocih in mladostnikih, starih od tri do 17 let, ki predhodno še niso bili zdravljeni.
Rebetol must not be used in patients with severe heart disease and blood disorders such as thalassaemia and sickle cell anaemia or in pregnant or breast-feeding women. 
Zdravilo Rebetol se ne sme uporabljati pri bolnikih z resnim obolenjem srca in krvnimi motnjami, kot sta talasemija in anemija srpastih celic, ali pri ženskah, ki so noseče ali dojijo.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rebetol. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Treatment with Rebetol should be started and monitored by a doctor who has experience in the management of long-term hepatitis C. 
Zdravljenje z zdravilom Rebetol mora predpisati in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem dolgotrajnega hepatitisa C.
Rebetol on its own has no effect on eliminating the hepatitis C virus from the body. 
Zdravilo Rebetol kot samostojno zdravilo nima nikakršnega učinka na odstranitev virusa hepatitisa C iz telesa.
Why has Rebetol been approved? 
Zakaj je bilo zdravilo Rebetol odobreno?
Combination treatment including Rebetol was effective in around a quarter of the adults whose disease had come back after previous treatment or whose previous treatment did not work, and over half of the children and adolescents treated. 
Kombinirano zdravljenje z zdravilom Rebetol je bilo učinkovito pri približno četrtini odraslih, pri katerih se je bolezen ponovila po predhodnem zdravljenju ali pri katerih predhodno zdravljenje ni bilo učinkovito, in pri več kot polovici zdravljenih otrok in mladostnikov.
In children weighing between 47 and 65 kg the dose ranges from 3 to 4 capsules. 
Pri otrocih, ki imajo telesno maso med 47 in 65 kg, znaša odmerek od tri do štiri kapsule.
In most of the studies, the main measure of effectiveness was the amount of virus in the blood before and after six months or a year of treatment, and at ‘follow-up', six months later. 
V večini študij je bilo glavno merilo učinkovitosti delež virusa v krvi pred zdravljenjem, po šestih mesecih ali enem letu zdravljenja ter ob kontrolnem pregledu šest mesecev pozneje.
The main measure of effectiveness in these studies was the number of patients who had no detectable hepatitis C virus in their blood 24 weeks after the end of the treatment and could therefore be considered to be cured. 
Glavno merilo učinkovitosti v teh študijah je bilo število bolnikov, pri katerih 24 tednov po zaključku zdravljenja v krvi ni bilo zaznanega virusa hepatitisa C, kar pomeni, da so bili ozdravljeni.
Rebetol is a medicine that contains the active substance ribavirin. 
Rebetol je zdravilo, ki vsebuje zdravilno učinkovino ribavirin.
The haemolytic anaemia may affect a patient's heart function and lead to abnormal test values for substances such as uric acid and bilirubin in the blood. 
Vpliva lahko na bolnikovo delovanje srca in povzroči neobičajne vrednosti pri testiranjih za snovi kot sta sečna kislina in bilirubin v krvi.
The dose of Rebetol is based on the patient's body weight, and ranges from five to six capsules a day in adults. 
Odmerek zdravila Rebetol je določen na osnovi bolnikove telesne mase in znaša pri odraslih od pet do šest kapsul na dan.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Rebetol, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu z njim so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Rebetol is used in combination with other medicines to treat adults with long-term hepatitis C (a disease of the liver due to infection with the hepatitis C virus). 
Zdravilo Rebetol se uporablja v kombinaciji z drugimi zdravili za zdravljenje odraslih z dolgotrajnim hepatitisom C (boleznijo jeter zaradi okužbe z virusom hepatitisa C).
Rebetol is thought to interfere with the production or action of viral DNA and RNA, which are needed for viruses to survive and multiply. 
Zdravilo Rebetol naj bi vplivalo na nastajanje ali delovanje virusnih DNK in RNK, brez katerih virusi ne morejo preživeti ali se razmnoževati.
Haemolytic anaemia (anaemia caused by abnormal breakdown of red blood cells) is a common side effect (seen in between 1 and 10 patients in 100), usually during the first few weeks of treatment. 
Najpogostejši neželeni učinek zdravila Rebetol (opažen pri več kot 1 do 10 bolnikov od 100) je hemolitična anemija (anemija, ki je posledica neobičajnega razkroja rdečih krvničk), ki se običajno pojavi v prvih tednih zdravljenja.
The active substance in Rebetol, ribavirin, is an antiviral belonging to the class ‘nucleoside analogues'. 
Zdravilna učinkovina zdravila Rebetol, ribavirin, je protivirusna učinkovina, ki spada v razred nukleozidnih analogov.
Additional data from the published literature show the positive effects of ribavirin-containing medicines when taken in different combinations, including combinations with peginterferon alfa-2a and a class of medicines known as direct acting antivirals (or DAAs). 
Dodatne informacije iz objavljene literature kažejo pozitivne učinke zdravil, ki vsebujejo ribavirin, vzetih v različnih kombinacijah, vključno s kombinacijami s peginterferonom alfa-2a in razredom zdravil, znanim kot neposredno delujoča protivirusna zdravila.
Two main studies involving 1,503 adult patients with type 1 hepatitis C and compensated liver disease investigated the effect of ribavirin in a triple therapy combination with peginterferon alfa-2b and boceprevir. 
V dveh glavnih študijah, v katerih so sodelovali 1 503 odrasli bolniki s hepatitisom C tipa 1 in kompenzirano boleznijo jeter, so proučevali učinek ribavirina v trotirnem zdravljenju s peginterferonom alfa-2b in boceprevirjem.
In adults who had not been treated before, Rebetol in combination with interferon alfa 2b was more effective than interferon alfa 2b on its own, with 41% of the patients responding to the combination treatment and 16% to the interferon alone. 
Pri odraslih bolnikih, ki predhodno še niso bili zdravljeni, je bilo zdravilo Rebetol v kombinaciji z interferonom alfa-2b učinkovitejše od interferona alfa-2b, uporabljenega samostojno, pri čemer se je na kombinirano zdravljenje odzvalo 41 % bolnikov, na interferon, dajan samostojno, pa 16 % bolnikov.
For the full list of side effects reported with Rebetol, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Rebetol, glejte navodilo za uporabo.
Rebetol in combination with peginterferon alfa 2b was also effective in adults with cirrhosis or HIV. 
Zdravilo Rebetol v kombinaciji s peginterferonom alfa-2b je bilo učinkovito tudi pri odraslih s cirozo ali okužbo z virusom HIV.
How has Rebetol been studied? 
Kako je bilo zdravilo Rebetol raziskano?
Response rates were higher when Rebetol was used with peginterferon alfa 2b. 
Stopnja odziva je bila večja, kadar je bilo zdravilo Rebetol uporabljeno s peginterferonom alfa-2b.
Triple therapy led to a 30% increase in the number of previously untreated early responders who were cured after six months. 
Pri trotirnem zdravljenju se je število predhodno nezdravljenih bolnikov, ki so se zgodaj odzvali na zdravljenje in so bili po šestih mesecih ozdravljeni, povečalo za 30 %.
In the studies on triple therapy in patients with type 1 hepatitis C and compensated liver disease, ribavirin in combination with peginterferon alfa 2b and boceprevir was shown to be more effective than the dual combination with peginterferon alfa 2b alone. 
V študijah trotirnega zdravljenja bolnikov s hepatitisom C tipa 1 in kompenzirano boleznijo jeter se je zdravljenje z ribavirinom v kombinaciji s peginterferonom alfa-2b in boceprevirjem izkazalo za učinkovitejše od dvotirnega zdravljenja zgolj s peginterferonom alfa-2b.
In all of the studies, Rebetol was given in combination with interferon alfa-2b or peginterferon alfa-2b. 
V vseh študijah je bilo zdravilo Rebetol dajano v kombinaciji z interferonom alfa-2b ali peginterferonom alfa-2b.
What is Rebetol? 
Kaj je zdravilo Rebetol?
How is Rebetol used? 
Kako se zdravilo Rebetol uporablja?
What is Rebetol used for? 
Za kaj se zdravilo Rebetol uporablja?
The Committee noted that Rebetol in combination with other medicines, including peginterferon alfa and DAAs is effective against long-term hepatitis C virus infection in adults and children. 
Menil je, da je zdravilo Rebetol v kombinaciji z drugimi zdravili, vključno z interferonom alfa-2b in neposredno delujočimi protivirusnimi zdravili, učinkovito pri dolgotrajni okužbi z virusom hepatitisa C pri odraslih in otrocih.
A 40% increase was seen among patients who had been treated before. 
Pri predhodno zdravljenih bolnikih je to povečanje znašalo
How does Rebetol work? 
Kako zdravilo Rebetol deluje?
This summary was last updated on: 02-2013. 
Ta povzetek je bil nazadnje posodobljen: 02-2013.
Recocam meloxicam 
Recocam meloksikam
A second dose may be given after 24 hours if required. 
Drugi odmerek lahko po potrebi sledi po 24 urah.
The European Commission granted a marketing authorisation valid throughout the European Union, for Recocam on 13/09/2011. 
Evropska komisija je dovoljenje za promet z zdravilom Recocam, veljavno po vsej Evropski uniji, odobrila dne 13/09/2011.
In very rare cases anaphylactoid reactions may occur and should be treated symptomatically. 
V zelo redkih primerih se lahko pojavijo anafilaktične reakcije, ki jih je treba zdraviti simptomatsko.
Other information about Recocam: 
Druge informacije o zdravilu Recocam:
It is available as a clear yellow solution for injection (20 mg/ml). 
Na voljo je v obliki bistre rumene raztopine za injiciranje (20 mg/ml).
In horses, a transient swelling at the injection site can occur but resolves without intervention. 
Pri konjih se lahko pojavi prehodna oteklina na mestu injiciranja, vendar uplahne brez ukrepanja.
The withdrawal period for Recocam for meat is 15 days for cattle and five days for pigs and horses. 
Obdobje karence za zdravilo Recocam je pri govedu 15 dni, pri prašičih in konjih pa 5 dni.
Meloxicam acts by blocking an enzyme called cyclo-oxygenase which is involved in the production of prostaglandins. 
Meloksikam deluje tako, da zavira encim, imenovan ciklo-oksigenaza, ki sodeluje pri tvorjenju prostaglandinov.
Although Recocam is a generic medicine no bioequivalence studies have been provided as the composition of the product is sufficiently similar to the reference product Metacam for the products to be considered essentially similar. 
Čeprav je zdravilo Recocam generično zdravilo, niso bile predložene nobene študije biološke enakovrednosti, saj je sestava zdravila dovolj podobna referenčnemu zdravilu Metacam, da se zdravili lahko v osnovi štejeta za podobni.
What benefit has Recocam shown during the studies? 
Kakšne koristi je zdravilo Recocam izkazalo med študijami?
People who are hypersensitive (allergic) to NSAIDs should avoid contact with Recocam. 
Osebe, ki so preobčutljive za (alergične na) nesteroidna protivnetna zdravila, naj se izogibajo stiku z zdravilom Recocam.